Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Rheumatoid arthritis tied to less breastfeeding, earlier cessation

08 Sep 2019

Rheumatoid arthritis appears to contribute to lower proportions of women breastfeeding their offspring and earlier cessation compared with the general population, a study has shown.

“A considerable number of patients discontinued breastfeeding so that they could start medication, even though many of the medications are considered safe to use during lactation,” the authors said.

This study, which was embedded in the nationwide prospective cohort PARA* study, sought to compare breastfeeding frequencies and time of cessation between women with RA and the general population, and to identify why patients with RA discontinued breastfeeding.

The authors followed a total of 249 pregnancies from pregnancy until 6 months postpartum from 2002 to 2008 and collected data on lactation and medication use. Percentages of breastfeeding between the study population and the general/reference population were compared using proportion tests.

Of the RA patients, 43 percent breastfed their offspring at 4–6 weeks postpartum, 26 percent at 12 weeks and 9 percent at 26 weeks compared with 63 percent, 46 percent and 41 percent in the general population, respectively (p<0.001).

Women discontinued breastfeeding primarily due to the restart of their medication (n=129; 57.8 percent). Of note, >40 percent of these patients restarted medication that was considered safe for breastfeeding.

“Using the results of this study, intervention strategies supporting RA patients who wish to breastfeed may be developed,” the authors said.

The World Health Organization recommends exclusive breastfeeding for infants until the age of 6 months, the authors noted.

*Pregnancy-induced Amelioration of Rheumatoid Arthritis

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.